Outlook Therapeutics develops ONS-5010/LYTENAVA, an eye treatment based on bevacizumab for wet macular degeneration. It last closed at $0.39 on Nov 20, down 2.74% on the day. The next earnings report for OTLK is expected around Fri, Dec 18, 2026. For the quarter ended Jun 2026, OTLK reported EPS of -$0.15. Over its last 8 reports the stock moved an average of 8.2% the session after earnings. Over the last 12 months OTLK insiders bought $7.9M of stock on the open market and sold $0, according to SEC Form 4 filings.
AI Auto Pilots
Is OTLK in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold OTLK.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on OTLKStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
OTLK · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold
The stock is 16% below its 20 day and 38% below its 50 day average. It is 69% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the Pivot at $0.38, and the nearest resistance the Pivot R1 at $0.41.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 11.5%/day
Key levels
$2.5452 week high+551.3%
$0.78100 day average+100.0%
$0.66200 day average+69.2%
$0.5450 day average+38.5%
$0.50Swing high (Nov 11)+28.2%
$0.4520 day average+15.4%
$0.41Pivot R1+5.1%
$0.39Last close
$0.38Pivot−2.6%
$0.37Pivot S1−5.1%
$0.35Swing low (Nov 17)−10.3%
$0.1652 week low−59.0%
Indicators
RSI (14)
36.03
Weak, oversold below 30
Neutral
MACD
-0.04
Below its signal line
Bearish
Stochastic
33.5
Middle of its range
Neutral
ADX (14)
25.5
Trending down
Williams %R
-73.0
Oversold below −80, overbought above −20
Neutral
CCI (20)
-125.1
Oversold below −100, overbought above 100
Oversold
Rate of change
−10.6%
Change over 10 sessions
Bearish
ATR (14)
$0.04
Typical daily range, 11.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 49.0%/day
Key levels
$2.5452 week high+551.3%
$0.78100 day average+100.0%
$0.66200 day average+69.2%
$0.5450 day average+38.5%
$0.50Swing high (Nov 11)+28.2%
$0.4520 day average+15.4%
$0.41Pivot R1+5.1%
$0.39Last close
$0.38Pivot−2.6%
$0.37Pivot S1−5.1%
$0.35Swing low (Nov 17)−10.3%
$0.1652 week low−59.0%
Indicators
RSI (14)
35.96
Weak, oversold below 30
Neutral
MACD
-0.13
Below its signal line
Bearish
Stochastic
4.4
Near the bottom of its range
Oversold
ADX (14)
15.3
No clear trend
Williams %R
-91.1
Oversold below −80, overbought above −20
Oversold
CCI (20)
-88.3
Oversold below −100, overbought above 100
Neutral
Rate of change
−40.9%
Change over 10 sessions
Bearish
ATR (14)
$0.19
Typical daily range, 49.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for OTLK
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how OTLK did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow OTLK usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for OTLKHow many large options trades hit OTLK, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in OTLK in the last 90 days.
From SEC Form 4 filings by OTLK's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OTLK is in one of them and how their past OTLK trades turned out.
Outlook Therapeutics is a biopharmaceutical company based in Iselin, New Jersey. Its main product is ONS-5010/LYTENAVA, an eye treatment based on bevacizumab, an antibody first approved for cancer and adapted for use in the eye. It is used to treat wet macular degeneration, a condition that can damage central vision. The product is approved in the European Union and the United Kingdom, where the company sells it directly, and it is under review in the United States.